362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series

BACKGROUND: A variant-adapted bivalent BNT162b2 vaccine (bivalent BNT162b2) comprised of original SARS-CoV-2 and Omicron BA.4/BA.5 spike proteins was developed to improve protection against SARS-CoV-2 variants. Bivalent BNT162b2 is authorized by the US FDA from 6 months (mo) old; for children 6 mo t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sher, Lawrence, Sabharwal, Charu, Kitchin, Nicholas, Kofi Boakya-Appiah, Justice, Xu, Xia, Walter, Emmanuel, Maldonado, Yvonne A, Munoz, Flor M, Englund, Janet A, Talaat, Kawsar R, Senders, Shelly, Kamidani, Satoshi, Barnett, Elizabeth, Paulsen, Grant C, Moyer, Lisa, Parikh, Vrunda, Ma, Hua, Wang, Xingbin, Koury, Kenneth, Anderson, Annaliesa S, Swanson, Kena A, Gurtman, Alejandra C, Gruber, William C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676853/
http://dx.doi.org/10.1093/ofid/ofad500.432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676853/
http://dx.doi.org/10.1093/ofid/ofad500.432

Ejemplares similares